Product News

Share this article:
GlaxoSmithKline says the US launch of HPV vaccine Cervarix will feature a slightly lower price than that of Merck's vaccine Gardasil, the Financial Times reports. GSK's new entrant will carry a wholesale cost of $386 for a three-course dose, compared with $399 for rival Gardasil, making the GSK vaccine more attractive for payers. The price strategy already has helped GSK win a vaccine contract in the UK.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.